{"entity":{"id":"nct06955325","kind":"trial","name":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","aka":["UPLIFT"],"tldr":"A phase 3 trial of icotinib, ensartinib and benmelstobart in lung cancer, run by The First Affiliated Hospital of Guangzhou Medical University, not yet recruiting.","summary":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations is a phase 3, randomised interventional study registered as NCT06955325 by The First Affiliated Hospital of Guangzhou Medical University, with a registry enrolment figure of 270 participants, started 2025-05 and due to reach its primary completion in 2030-12. Interventions recorded: Icotinib; Rezivertinib; Ensartinib; Benmelstobart. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Disease-Free Survival (DFS). Lung eligibility wording from the registry: \"* Primary non-squamous NSCLC confirmed by pathology, with no brain metastases\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06955325","url":"https://clinicaltrials.gov/study/NCT06955325"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["icotinib","ensartinib","benmelstobart"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06955325","phase":"3","setting":"A Randomized, Phase III Umbrella Trial of Adjuvant Therapy Versus Observation in Completely Resected High-Risk Stage IA-IB Non-Small Cell Lung Cancer Based on Oncogenic Driver Mutations","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","enrolled":270,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06955325/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"benmelstobart","kind":"drug","name":"Benmelstobart","route":"/drugs/benmelstobart/"},{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/"},{"id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}